S. Rayavarapu

发表

Understanding the Pathogenesis of Muscle Diseases Using In vivo SILAC Proteomic Strategy

S. Rayavarapu, Sree Rayavarapu, 2013 .

Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice

K. Nagaraju, S. Rayavarapu, Margaret E Benny Klimek, 2016, PloS one.

Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Kristy Brown, E. Hoffman, Y. Hathout, 2014, Human molecular genetics.

Measurement of activation of the endoplasmic reticulum stress response in autoimmune myositis.

Heather M. Alger, K. Nagaraju, S. Rayavarapu, 2011, Methods in enzymology.

Endoplasmic Reticulum Stress in Skeletal Muscle Homeostasis and Disease

K. Nagaraju, S. Rayavarapu, William D Coley, 2012, Current Rheumatology Reports.

Effect of genetic background on the dystrophic phenotype in mdx mice.

C. Lutz, K. Nagaraju, T. Partridge, 2016, Human molecular genetics.

AMP‐activated protein kinase signaling regulated expression of urea cycle enzymes in response to changes in dietary protein intake

M. Tuchman, Kristy Brown, Y. Hathout, 2019, Journal of inherited metabolic disease.

The effects of MyD88 deficiency on disease phenotype in dysferlin‐deficient A/J mice: role of endogenous TLR ligands

E. Hoffman, K. Uaesoontrachoon, K. Nagaraju, 2013, The Journal of pathology.

Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice

C. Spurney, K. Nagaraju, E. Gallardo, 2015, Journal of the Neurological Sciences.

Glucocorticoid analogues: potential therapeutic alternatives for treating inflammatory muscle diseases.

K. Nagaraju, S. Rayavarapu, J. Damsker, 2012, Endocrine, metabolic & immune disorders drug targets.

Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.

E. Hoffman, K. Nagaraju, F. Miller, 2016, Rheumatology.

Pathogenesis of myositis: Lessons learned from animal studies

K. Nagaraju, S. Rayavarapu, K. White, 2013 .

Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis

K. Nagaraju, S. Rayavarapu, William D Coley, 2013, PloS one.

The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

G. S. Pandey, R. Wortmann, K. Nagaraju, 2012, Arthritis and rheumatism.

Δ-9,11 Modification of Glucocorticoids Dissociates Nuclear Factor-κB Inhibitory Efficacy from Glucocorticoid Response Element-Associated Side Effects

E. Hoffman, D. DuBois, J. Mccall, 2012, Journal of Pharmacology and Experimental Therapeutics.

Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy2J Mouse Model of Congenital Muscular Dystrophy

K. Uaesoontrachoon, C. Spurney, K. Nagaraju, 2013, PloS one.

Elusive sources of variability of dystrophin rescue by exon skipping

Kristy Brown, E. Hoffman, Y. Hathout, 2015, Skeletal Muscle.

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy

Kristy Brown, Y. Hathout, J. Jaiswal, 2016, Cell Death and Differentiation.

Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle.

S. Agrawal, K. Nagaraju, H. Cha, 2014, Human molecular genetics.

An update on pathogenic mechanisms of inflammatory myopathies

K. Nagaraju, S. Rayavarapu, William D Coley, 2011, Current opinion in rheumatology.

AMPK signaling regulates expression of urea cycle enzymes in response to changes in dietary protein intake

M. Tuchman, Y. Hathout, K. Nagaraju, 2018, bioRxiv.

Pentoxifylline as a rescue treatment for DMD

J. Florence, A. Kornberg, A. Connolly, 2012, Neurology.

Identification of Disease Specific Pathways Using in Vivo SILAC Proteomics in Dystrophin Deficient mdx Mouse*

E. Hoffman, Y. Hathout, J. Jaiswal, 2013, Molecular & Cellular Proteomics.

Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry.

E. Hoffman, Y. Hathout, Seema Sharma, 2012, Journal of bioanalysis & biomedicine.

Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies

K. Nagaraju, S. Rayavarapu, William D. Coley, 2012, Arthritis Research & Therapy.

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

K. Nagaraju, S. Rayavarapu, Travis B. Kinder, 2013, Skeletal Muscle.

Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice

Eric P Hoffman, Kanneboyina Nagaraju, Heather Gordish-Dressman, 2011, Journal of cardiovascular pharmacology and therapeutics.

Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype

E. Hoffman, K. Nagaraju, S. Rayavarapu, 2010, PloS one.

Use of Quantitative Membrane Proteomics Identifies a Novel Role of Mitochondria in Healing Injured Muscles*

Y. Hathout, J. Jaiswal, S. Rayavarapu, 2012, The Journal of Biological Chemistry.

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Kanneboyina Nagaraju, K. Nagaraju, S. Rayavarapu, 2013, Skeletal Muscle.

Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target.

Y. Hathout, E. Çakır, K. Nagaraju, 2013, Arthritis and rheumatism.

The use of proteomic analysis to study trafficking defects in axons.

K. Nagaraju, Xiaoqin Fu, S. Rayavarapu, 2016, Methods in cell biology.

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse

E. Hoffman, Y. Hathout, K. Uaesoontrachoon, 2015, Toxicology reports.